This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

National Survey on Infiltrative Breast Cancer (CSI)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: June 10, 2008
Last updated: December 9, 2010
Last verified: December 2010
The purpose of this observational study is to describe radiological, clinical and histological characteristics of women with infiltrative breast cancer.

Infiltrative Breast Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: National Prospective Survey on Women With a Diagnosis of Infiltrative Breast Cancer

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Radiological, Clinical and Histological characteristics [ Time Frame: Once ]

Secondary Outcome Measures:
  • Treatments: Surgery, radiotherapy, chemotherapy, hormonotherapy. [ Time Frame: Once ]

Estimated Enrollment: 1500
Study Start Date: June 2007
Study Completion Date: July 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
First ten consecutive women with infiltrative breast cancer seen by oncologists, and fulfilling eligibility criteria.

Inclusion Criteria:

  • Women> or = 18 years old
  • Women with newly diagnosis of infiltrative breast cancer
  • Agree to take part in this study

Exclusion Criteria:

  • Women with other malignant tumor (except in situ cervical carcinoma or treated basal cell carcinoma)
  • Women with in situ ductal carcinoma or in situ lobular carcinoma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00696527

  Show 136 Study Locations
Sponsors and Collaborators
Study Director: Alain Castaigne, Medical Director AstraZeneca
  More Information

Responsible Party: Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals Identifier: NCT00696527     History of Changes
Other Study ID Numbers: NIS-OFR-DUM-2007/1
Study First Received: June 10, 2008
Last Updated: December 9, 2010

Keywords provided by AstraZeneca:
Infiltrative breast cancer-Clinical practice
Women with infiltrative breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases processed this record on August 17, 2017